Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA

ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Prof. Paul Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, and Eugene Braunwald Professor of Medicine at Harvard School of Medicine.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Listen to Paul Ridker discussing the CKD results of the CANTOS trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.